Search Contract Opportunities

Renewal of Schrodinger Small Molecule Drug Discovery Suite software license

ID: 75N95020Q00284 • Type: Synopsis Solicitation

Description

NON-COMPETITIVE
COMBINED SYNOPSIS / SOLICITATION

Title: Renewal of Schrodinger Small Molecule Drug Discovery Suite software license

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

(ii) The solicitation number is 75N95020Q00284 and solicitation is issued as a request for quotation.
This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures and FAR Part 12 Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), NIDA Office of Acquisition NCATS Section, on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Schrodinger, L.L.C., 101 SW Main Street, Ste 1300, Portland, OR 97204, for renewal of licenses for the Small Molecule Drug Discovery Suite software. The anticipated award date is September 2, 2020.

This acquisition is non-competitive due to exclusive license agreements governing this commercial software. See FAR 13.106(b).

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2020-08 dated 8/13/2020.

(iv) The associated NAICS code is 511210 and the small business size is $41.5 million. The requirement is not set aside for small business.

(v) This acquisition consists of:

Line 0001: Schrodinger Small Molecule Drug Discovery Suite.

(vi) Delivery shall be to:

The National Center for Advancing Translational Sciences (NCATS)
9800 Medical Center Drive
Rockville, MD 20850

Delivery shall be by September 3, 2020, FOB destination.

(vii) The provision at FAR clause 52.212-1, Instructions to Offerors Commercial Items, applies to this acquisition.

(viii) The award resulting from this solicitation will be made to the responsible offeror whose proposal is most advantageous to the Government, price and other factors considered.

(ix) Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications Commercial Items, with offers.

(x) The FAR clause at 52.212-4, Contract Terms and Conditions Commercial Items, applies to this acquisition. The following addendum applies:

FAR 52.212-4 Addendum Supplier License Agreements, attached.

The following FAR provisions or clauses are incorporated by reference:

52.204-7, System for Award Management (Oct 2018)
52.204-13, System for Award Management Maintenance (Oct 2018)
52.204-16, Commercial and Entity Code Reporting (Aug 2020)
52.204-18, Commercial and Entity Code Maintenance (Aug 2020)
HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015).

52.212-4(g), Invoice, is supplemented by the NIH Invoice and Payment Instructions (2/2014), and the NIH interim electronic invoice submission instructions, attached.

Offerors must complete and return the FAR representation 52.204-24 Representation Regarding Certain Telecommunicaitons and Video Surveillance Services or Equipment (Aug 2020), attached.

(xi) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items, applies to this acquisition, and is attached.

(xii) This synopsis is not a request for competitive proposals. All responsible sources may submit a bid, proposal or quotation which shall be considered by the agency.

(xvi) In addition, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by 11:00 a.m. Eastern Time on Monday, August 31, and reference solicitation number 75N95020Q00284. Responses must be submitted by email to Stuart Kern, Contract Specialist, stuart.kern@nih.gov, tel. 301-402-3334.

Overview

Response Deadline
Aug. 31, 2020, 11:00 a.m. EDT Past Due
Posted
Aug. 26, 2020, 9:28 a.m. EDT
Set Aside
None
Place of Performance
Rockville, MD 20850 United States
Source
SAM

Current SBA Size Standard
$41.5 Million
Pricing
Likely Fixed Price
Est. Level of Competition
Low
Signs of Shaping
The solicitation is open for 5 days, below average for the National Institute on Drug Abuse.
On 8/26/20 National Institute on Drug Abuse issued Synopsis Solicitation 75N95020Q00284 for Renewal of Schrodinger Small Molecule Drug Discovery Suite software license due 8/31/20. The opportunity was issued full & open with NAICS 511210 and PSC 7030.
Primary Contact
Name
Stuart Kern   Profile
Phone
(301) 402-3334

Documents

Posted documents for Synopsis Solicitation 75N95020Q00284

Question & Answer

Contract Awards

Prime contracts awarded through Synopsis Solicitation 75N95020Q00284

Incumbent or Similar Awards

Potential Bidders and Partners

Awardees that have won contracts similar to Synopsis Solicitation 75N95020Q00284

Similar Active Opportunities

Open contract opportunities similar to Synopsis Solicitation 75N95020Q00284

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > NATIONAL INSTITUTES OF HEALTH > NATIONAL INSTITUTES OF HEALTH NIDA
FPDS Organization Code
7529-75N950
Source Organization Code
100189048
Last Updated
Sept. 15, 2020
Last Updated By
PI33_DR_IAE_51681
Archive Date
Sept. 15, 2020